Skip to main content
Equibles
AGL logo

AGL · agilon health, inc. · Metrics

Track AGL — free

Use AGL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AGL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$89.71 -0.58 (-0.64%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$1.51B
Shares
16.79M
Volume · Oct 23 189.62K Avg daily vol (3M) 264.17K

AGL metrics

76 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$89.71
Market cap
$1.51B

Price action

20 metrics
Price change (1W)
+5.4%
Price change (30D)
+11.1%
Price change (3M)
-8.5%
Price change (6M)
+242.3%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
190.2%
Annualized volatility (3M)
73.3%
Beta
1.6
RSI (14D)
54.6
Price vs SMA 50
+1.3%
Price vs SMA 200
—
Avg volume (3M)
264,166
Relative volume
0.7
Average dollar volume
$24.02M

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
16.79M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.2×
reciprocal yield 414.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.3×
reciprocal yield 393.0%
P / book
6.6
reciprocal yield 15.1%
FCF yield
-5.6%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-15.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.4×
reciprocal yield 280.4%
EV / revenue historical average (5Y)
1.4×
reciprocal yield 72.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-04
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
-5.2%
Trailing 12 months
Net margin
-3.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$309.33M
Net income (TTM)
−$232.22M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-1.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$353.30
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-18.68
EBITDA per diluted share (TTM)
$-17.01
Net income per diluted share (TTM)
$-14.06
Operating cash flow per diluted share (TTM)
$-4.24
Free cash flow per diluted share (TTM)
$-4.99
Capital expenditures per diluted share (TTM)
$0.76
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$2.79
Book value per share
$7.64

Growth

11 metrics
Revenue growth YoY
+7.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$5.92B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+4.0%
Year over year · more shares
Revenue CAGR (3Y)
+35.4%
Revenue CAGR (5Y)
+37.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-102.1%
Return on assets
-14.6%
Debt / equity
0.1
Current ratio
1.1
EBITDA (TTM)
−$281.28M
Free cash flow (TTM)
−$84.95M
Quick ratio
1.1
Interest coverage
-44.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$76.89M
Latest balance sheet
Cash & equivalents
$107.18M
Total assets
$1.59B
Total debt
$30.29M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$72.26M
Capital expenditures (TTM)
$12.69M
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$47.10M
R&D / revenue
—
Stock compensation / revenue
0.8%

Ownership (13F)

9 metrics
13F filers
180
13F filer change QoQ
+80
Institutional ownership
103.0%
Conviction holders (share of 13F filers)
2.2%
Crowding (high-turnover and private-fund holders)
52.8%
Private-fund adviser ownership
48.1%
Active holders' share change QoQ
+13.7%
Holder tenure
13.1
Price vs estimated holder cost
-80.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.6%

Short interest

3 metrics
Short interest
6.0%
Latest settlement · 3.8 days to cover
Days to cover
3.8d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1831097 CUSIP 00857U206 13F (30d) 23 filings 23 filers Visit website Investor relations